USANA HEALTH SCIENCES INC (USNA): Results of Operations and Financial Condition
USANA HEALTH SCIENCES INC (USNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. USANA Health Sciences Reports Second Quarter 2026 Results Company Continues Evolution to a Diversified, Omnichannel Health and Wellness Business SALT LAKE CITY, August 4, 2026 (BUSINESS WIRE)—USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fisca
How this was made
The 30-second read
Why it matters
Key trading drivers are the Q2 deterioration (net loss, adjusted EPS loss), the preliminary non-cash goodwill impairment related to Hiya, and the full-year guidance reset that lowers expected Hiya and Rise net sales and reduces consolidated net sales and earnings ranges.
Market read
Traders should focus on the guidance reset and impairment disclosure, which directly change the earnings trajectory and risk assessment for USNA’s venture strategy.
What to watch
The impairment is non-cash, and the company ended the quarter with $169M cash and zero debt, plus $20M free cash flow, which may cushion downside if execution stabilizes.
Background
USANA filed an 8-K with Q2 2026 results (fiscal quarter ended July 4, 2026) and an updated FY2026 outlook for its Core Nutritional, Hiya, and Rise Wellness businesses.
Ticker impact
USANA reported Q2 2026 results and updated FY2026 guidance, including a $29.1M non-cash goodwill impairment tied to Hiya performance.
Likely negative near-term bias as traders reprice FY2026 net sales and adjusted EPS expectations after the Hiya and Rise execution issues.
The filing discloses concrete, time-sensitive changes: net loss and adjusted EPS deterioration in Q2, a preliminary goodwill impairment, and a full-year outlook reduction for Hiya and Rise.
Market effects
Signals stress in omnichannel health and wellness ventures (Hiya, Rise) and potential margin pressure from digital marketing and execution disruptions.
Asia Pacific remains the largest growth engine in the segment mix, but Greater China and North Asia show mixed trends.
Limited broader macro spillover; primarily company-specific repricing of USNA’s venture economics.
Counterpoint
USANA frames Hiya and Rise issues as temporary and emphasizes ongoing transformation, product innovation, and technology modernization.
Key entities
- issuerUSANA Health Sciences, Inc.
Reported Q2 2026 results and updated FY2026 guidance, including a preliminary $29.1M goodwill impairment tied to Hiya.
- business_unitHiya
Omnichannel venture with weaker digital marketing conditions; performance drove the goodwill impairment and guidance reduction.
- business_unitRise Wellness
Protein beverage venture impacted by a packaging-related disruption; guidance lowered for full-year net sales.
- executiveKevin Guest
CEO quoted on mixed quarter performance and the updated outlook.
- executiveDoug Hekking
CFO quoted on the impairment rationale and tax-rate impact on net loss.
